Was wir denken

Erfahren Sie mehr über unsere neuesten Einblicke, Ideen und Perspektiven. Hier finden Sie einen Ausblick auf unserer aktuellen Erkenntnisse und Denkanstöße für verschiedene Industrien und Branchen.

Trending Topics

The Growth Blueprint podcast
Automotive Study
The new economics of neobanking
2024 Global Telecommunications Study results
Global Pricing Study 2025
Tariffs, pricing, and power
Wie kommen Unternehmen durch eine mögliche Rezession?
Durch Revenue Growth Management neue Wachstumspotenziale erschließen
Better Growth
Europe
latest report by Simon-Kucher and the German Association of Research-Based Pharmaceutical Companies (vfa)
Jan. 06, 2025 | Perspective | Report

Die Bedeutung der Orphan Drug-Regelung im AMNOG für die Patientenversorgung

Healthcare & Life Sciences Pharma & Biotechnologie
Americas
Simon-Kucher insights: CMS releases FY 2027 IPPS final rule
Aug 26, 2026 | Blog

CMS releases FY 2027 IPPS final rule

Healthcare & Life Sciences Pharma & Biotechnology
SK insights: Commercializing emerging biotech markets
Aug 25, 2026 | Blog

Commercializing emerging biotech markets

Healthcare & Life Sciences Pharma & Biotechnology
Global
Simon-Kucher insight: AI in pharma tender management
Aug 21, 2026 | Blog

AI in pharma tender management

Healthcare & Life Sciences Pharma & Biotechnology
Americas
Simon-Kucher insights: CY 2027 MPFS proposed rule: What to watch out for
Aug 20, 2026 | Blog

CY 2027 MPFS proposed rule: What to watch out for

Healthcare & Life Sciences Pharma & Biotechnology
Middle east and APAC
Simon-Kucher insights: NRDL 2026: What's changed, what's at stake
Aug 13, 2026 | Blog

NRDL 2026: What's changed, what's at stake

Healthcare & Life Sciences Pharma & Biotechnology
Global
Christian Schuler
Juli 28, 2026 | Blog

Pharma & biotech mid-year trends 2026

Healthcare & Life Sciences Pharma & Biotechnology
United States
CY 2027 OPPS and ASC: Implications for manufacturers
Juli 22, 2026 | Blog

CY 2027 OPPS and ASC: Implications for manufacturers

Healthcare & Life Sciences Pharma & Biotechnology
Middle east and APAC
Simon-Kucher insights: Korea pharma market access: Inside the 2026 drug pricing policy reforms
Juli 13, 2026 | Blog

Three reforms to move Korea up the global drug launches

Healthcare & Life Sciences Pharma & Biotechnology
whitepaper
Juni 19, 2026 | Perspective | Whitepaper

What MFN means for early-stage biotech

Healthcare & Life Sciences Pharma & Biotechnology
biotech whitepaper
Juni 19, 2026 | Perspective | Whitepaper

Executing under MFN: Commercialization choices for late-stage biotechs

Healthcare & Life Sciences Pharma & Biotechnology
Global
pills scattered on the glass table
Juni 15, 2026 | Blog

Global pharma P&MA trends in 2026

Healthcare & Life Sciences Pharma & Biotechnology
Global
Blog header_Winning evidence strategies for orphan drugs
Juni 15, 2026 | Blog

Winning RWE evidence strategies for orphan drugs

Healthcare & Life Sciences Pharma & Biotechnology
Americas
Blog header_The possible scenarios of MFN drug pricing in pharma
Juni 11, 2026 | Blog

The possible scenarios of MFN drug pricing in pharma

Healthcare & Life Sciences Pharma & Biotechnology
Global
Blog header image_Beyond pricing: How MFN may reshape pharma dealmaking
Juni 08, 2026 | Blog

How MFN may reshape pharma dealmaking beyond pricing

Healthcare & Life Sciences Pharma & Biotechnology
Americas
MFN puts pharma between Scylla and Charybdis
Juni 03, 2026 | Blog

MFN puts pharma between Scylla and Charybdis

Healthcare & Life Sciences Pharma & Biotechnology
Language
Search